Abstract
The use of murine monoclonal antibodies as targeting agents for the treatment of malignancies is ironically precluded by the patient’s own antimouse antibody (HAMA) response1-3. Human monoclonal antibodies should be tolerated, but unfortunately, they have not been forthcoming because of various technical difficulties. A number of recent advances, however, should circumvent these difficulties. Promising antibodies expressed by unstable human hybridomas or produced in low amounts, can now be salvaged by cloning their variable region-encoding cDNAs and splicing them into vectors encoding human constant regions. These are then transfected into stable murine myeloma cell lines. Another possibility for the production of useful human monoclonal antibodies is by panning phage display libraries4, a process that requires no immunization. A new generation of human monoclonal antibodies should not, however, displace good murine antibodies that have resulted from years of arduous labor and minutious characterization since these murine antibodies may have uniquely useful binding properties, and since they can be humanized.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Schroff, R.W., Foon, K.A., Beatty, S.M., Oldham, R.K., and Morgan, A.C. Jr., Human anti-murine immunoglobulins responses in patients receiving monoclonal therapy. Cancer Res., 45: 879–885 (1985).
Shawler, D.L., Bartholomew, R.M., Smith, L.M., and Dillman, R.O. Human immune response to multiple injections of murine monoclonal IgG. J. Immunol, 135: 1530–1535 (1985).
Courtenay-Luck, N.S., Epenetos, A.A., Moore, R., Larche, M., Pectasides, D., Dhokia, B. and Ritter, M.A. Development of primary and secondary immune responses to mouse monoclonal antibodies used in the diagnosis and therapy of malignant neoplasms. Cancer Res., 46: 6489–6493 (1986).
Marks JD; Hoogenboom HR; Griffiths AD; Winter G., Molecular evolution of proteins on filamentous phage. Mimicking the strategy of the immune system. J. Biol Chem. 267: 16007–16010 (1992).
Peterson, J.A., Zava D.T., Duwe, A.K., Blank, E.W., Battifora, H., and Ceriani R.L. Biochemical and histological characterization of antigens preferentially expressed on the surface and cytoplasm of breast carcinoma cells identified by monoclonal antibodies against the human milk fat globule. Hybridoma, 9: 221–235 (1990).
Peterson, J.A., Larocca D., Walkup G., Amiya R., and Ceriani R.L. Molecular analysis of epitope heterogeneity of the breast mucin. In: Breast epithelial antigens: Molecular biology to clinical applications. Ceriani R.L. (ed). Plenum Publications, New York (1991).
Blank, E.W., Pant, K.D., Chan, C.M., Peterson, J.A., and Ceriani, R.L. A novel anti-breast epithelial mucin MAb (BrE-3). Characterization and experimental biodistribution and immunotherapy. Cancer J., 5: 38–44 (1992).
Orlandi, R., Gussow, D.H., Jones, P.T., and Winter, G. Cloning immunoglobulin variable domains for expression by the polymerase chain reaction. Proc. Natl. Acad. Sci. USA, 86: 3833–3837 (1989).
Coloma, M.J., Larrick, J.W., Ayala, M., and Gavilondo-Cowley, J.V. Primer design for the cloning of immunoglobulin heavy-chain leader-variable regions from mouse hybridoma cells using the PCR. BioTechniques, 11: 152–156 (1991).
Gavilondo-Cowley, J.V., M., Vazquez, J., Ayala, M., Macias, A., Fry, K.E., and Larrick, J.W. Specific amplification of rearranged immunoglobulin variable region genes from mouse hybridoma cells. Hybridoma, 9: 407–417 (1990).
Kabat, E.A., Wu, T.T., Perry, H.M., Gottesman, K.S., and Foeller, C. Sequences of proteins of immunological interest. US. Dept. Health and Human Services, NIH publication No. 91–3242, 5th Edition (1991).
Couto, J.R., Blank, E.W., Peterson, J.A., and Ceriani, R.L., Cloning of cDNAs encoding the variable domains of antibody BrE-3 and construction of a chimeric antibody. Hybridoma, 12(1): 15–23 (1993).
Coloma, M.J., Hastings, A., Wims, L.A., and Morrison, S.L. Novel vectors for the expression of antibody molecules using variable regions generated by PCR. J. Immunol. Methods, 152:89–104 (1992).
Ceriani, R.L., Larocca, D., Peterson, J.A., Enloe, S., Amiya, R., and Blank, E.W. A novel serum assay for the breast epithelial antigen using a fusion protein. Anal Biochem., 201: 178–184 (1992).
Larocca, D., Peterson, J.A., Walkup, G., and Ceriani, R.L., High level expression in E. coli of an alternate reading frame of pS2 mRNA that encodes a mimitope of human breast epithelial mucin tandem repeat. Hybridoma, 11: 191–201 (1992).
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1994 Springer Science+Business Media New York
About this chapter
Cite this chapter
Couto, J.R., Blank, E.W., Peterson, J.A., Kiwan, R., Ceriani, R.L., Padlan, E.A. (1994). Engineering of Antibodies for Breast Cancer Therapy: Construction of Chimeric and Humanized Versions of the Murine Monoclonal Antibody BrE-3. In: Ceriani, R.L. (eds) Antigen and Antibody Molecular Engineering in Breast Cancer Diagnosis and Treatment. Advances in Experimental Medicine and Biology, vol 353. Springer, Boston, MA. https://doi.org/10.1007/978-1-4615-2443-4_7
Download citation
DOI: https://doi.org/10.1007/978-1-4615-2443-4_7
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4613-6038-4
Online ISBN: 978-1-4615-2443-4
eBook Packages: Springer Book Archive